Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points Market underestimating trough earnings power of the company with shares already trading at trough levels, in our view Valuation highly attractive on a normal basis. Positive valuation re-rating ......
Key Points We’re updating our forecast for CW post yesterday’s 1Q25 earnings report, and we’re raising our target price and reiterating our Overweight rating. Our target price rises USD28 to ......
Key Points Q1’25 EBITDA miss but EPS beat; higher EBITDA margins logged in every segment y-o-y Q2’25 guidance mid-point range below consensus levels We rate Trinseo shares Overweight; our 12-month ......
Key Points Company hitting commercialization and production milestones Multiple customer trials in progress; first ever reported revenue logged We rate PCT shares Overweight, with a USD18 per share 12-month target ......
Key Points We’re updating our forecast for MRCY post last night’s 3QFY25 earnings call and we’re raising our target price by USD3 to USD66. We’re using the same 22x terminal ......
Key Points Q1’25 EBITDA and EPS miss Q2’25 and FY2025 guidance more or less in line with consensus We rate CC shares Overweight, with a revised-lower 12-month target price of ......